Statins and renal function
- PMID: 12365855
- DOI: 10.1177/000331970205300501
Statins and renal function
Abstract
Renal disease is often associated with an increased risk of vascular events. Moreover, an accelerated form of atherosclerosis commonly occurs in these patients. The reasons for these associations are not clearly defined but include the widespread presence of several established risk factors (eg, dyslipidemia, hypertension, and diabetes). Other predictors of atherosclerotic disease may also be abnormally elevated (eg, homocysteine, fibrinogen, and lipoprotein a). In addition, there is evidence that impaired renal function per se predicts vascular risk. Despite this high-risk background, the potential benefit of treatment with statins has not been widely investigated in these patients. The present review considers the evidence (experimental and clinical) that statins exert beneficial effects in patients with different types of renal disease. This includes improved renal function, decreased microalbuminuria, and a fall in blood pressure. Statins may also improve renal allograft survival. The potential mechanisms mediating these effects are considered. The interactions between statins and several risk factors that may be present in patients with impaired renal function are also considered. There is an urgent need to define the role of statins in these high-risk patients. Which is the statin of choice? This question is relevant because impaired renal function can interfere with statin pharmacokinetics. Furthermore, other drugs administered to these patients may cause serious interactions with statins.
Similar articles
-
[Effects of atorvastatin on hyperlipidemia in kidney disease patients].Nihon Jinzo Gakkai Shi. 2007;49(1):41-8. Nihon Jinzo Gakkai Shi. 2007. PMID: 17299985 Japanese.
-
[Atherosclerosis in light of the evidence from large statin trials].Ann Ital Med Int. 2000 Jan-Mar;15(1):103-7. Ann Ital Med Int. 2000. PMID: 10842899 Review. Italian.
-
Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy.Ren Fail. 2010 Jul;32(6):680-6. doi: 10.3109/0886022X.2010.486493. Ren Fail. 2010. PMID: 20540635 Clinical Trial.
-
Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: a pilot study.Angiology. 2005 Jan-Feb;56(1):61-8. doi: 10.1177/000331970505600108. Angiology. 2005. PMID: 15678257
-
Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease.J Cardiovasc Pharmacol Ther. 2004 Mar;9(1):61-3. doi: 10.1177/107424840400900i109. J Cardiovasc Pharmacol Ther. 2004. PMID: 15094970 Review.
Cited by
-
Risks and benefits of statin use in young people with type 1 diabetes.Curr Diab Rep. 2014 Jul;14(7):499. doi: 10.1007/s11892-014-0499-8. Curr Diab Rep. 2014. PMID: 24796934 Free PMC article. Review.
-
Circulatory syndrome: an evolution of the metabolic syndrome concept!Curr Cardiol Rev. 2012 Feb;8(1):68-76. doi: 10.2174/157340312801215773. Curr Cardiol Rev. 2012. PMID: 22845817 Free PMC article. Review.
-
Treatment of lipids and type 2 diabetes.Curr Cardiol Rep. 2004 Nov;6(6):443-50. doi: 10.1007/s11886-004-0053-4. Curr Cardiol Rep. 2004. PMID: 15485606 Review.
-
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.J Clin Pathol. 2004 Jul;57(7):728-34. doi: 10.1136/jcp.2003.012989. J Clin Pathol. 2004. PMID: 15220366 Free PMC article. Clinical Trial.
-
The Association Between Statin Use and Risk of Chronic Kidney Disease in Community-Dwelling Older People in Shanghai, China.Clin Epidemiol. 2022 Jun 25;14:779-788. doi: 10.2147/CLEP.S360395. eCollection 2022. Clin Epidemiol. 2022. PMID: 35782995 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical